PharmaPoint: Healthcare-Associated Gram-Negative Infections – Global Drug Forecast and Market Analysis to 2026

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Healthcare-associated infections (HAIs) are a major threat to patient safety, and place a substantial economic burden on healthcare systems. HAIs occur in hospitalized patients, and are not present at the time of admission. Acute care hospitals are the primary settings for contracting HAIs, with a high concentration occurring within non-nursery wards and intensive care units (ICUs).The most common types of HAIs are related to the use of invasive devices or surgical procedures, and fall into the following infection site categories: catheter-associated urinary tract infection (CAUTI), central line-associated bloodstream infection (CLABSI), hospital-associated pneumonia/ventilator-associated pneumonia (HAP/VAP), and surgical site infection (SSI).
The pharmaceutical industry’s battle against Gram-negative bacteria requires ongoing development and novel, innovative approaches for the development of new antibiotics as well as non-antibiotic based approaches. Due to the lack of novel scaffolds being developed over the last few decades and limited investments into antibiotic R&D during this century, the prevalence of resistant Gram-negative bacteria, especially in the hospital setting, has increased significantly; antibiotic resistance is now considered a major threat to the life expectancy of current future generations, including in developed countries. Consequently, industry and governments have recently ramped up their involvement in this space, and several promising antibiotics are now in the late-stage development.


Overview of HAIs caused by Gram-negative bacteria, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.

Topline market revenue from 2016–2026 for HAIs caused by Gram-negative bacteria. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.

Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting therapeutics sales in the 7MM.

Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.

Analysis of the current and future market competition in the global therapeutics market for HAIs caused by Gram-negative bacteria. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

The report will enable you to:

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global therapeutics market for HAIs caused by Gram-negative bacteria.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the therapeutics market for HAIs caused by Gram-negative bacteria in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Merck & Co
The Medicines Company
Shionogi & Co Ltd
Tetraphase Pharmaceuticals Inc
MerLion Pharmaceuticals Pte Ltd
Aridis Pharmaceuticals
MedImmune LLC

Table of Contents

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Executive Summary

2.1 Launch of Patented Antibiotics Will Drive Solid Growth Over the Forecast Period

2.2 Pipeline Portfolios Target Highly Resistant Bacteria in Strong Collaborations With Governments

2.3 Drug Portfolios Address Some Unmet Needs, but Some Opportunities Remain With New Foreseeable Challenges

2.4 Companies Must Quickly Adapt to Exploit Opportunities in an Evolving Marketplace

2.5 Novel Antibiotics Are Poised to Drive Growth Despite Entering a Highly Genericized Marketplace

2.6 What Do Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

3.3 Upcoming Related Reports

4 Disease Overview

4.1 Infection Scope and Coverage Overview

4.2 Etiology and Pathophysiology

4.2.1 Etiology

4.2.2 Pathophysiology

4.3 Symptoms

4.4 Prognosis

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors and Comorbidities

5.3 Global and Historical Trends

5.3.1 US

5.3.2 5EU

5.3.3 Japan

5.4 Forecast Methodology

5.4.1 Sources

5.4.2 Forecast Assumptions and Methods

5.5 Epidemiological Forecast for Suspected HAIs and Gram-Negative HAIs (2016–2026)

5.5.1 Suspected Incident Cases of Select HAIs

5.5.2 Diagnosed Incident Cases of Select Gram-Negative HAIs

5.5.3 Suspected Incident Cases of Select HAIs by Infection Site

5.5.4 Diagnosed Incident Cases of Select Gram-Negative HAIs by Infection Site

5.5.5 Diagnosed Incident Cases of Select Gram-Negative HAIs by Causative Agent

5.6 Discussion

5.6.1 Epidemiological Forecast Insight

5.6.2 Limitations of the Analysis

5.6.3 Strengths of the Analysis

6 Disease Management

6.1 Diagnosis and Treatment Overview

6.1.1 Diagnosis

6.1.2 Treatment Guidelines

6.1.3 Clinical Practice

6.1.4 Antibiotic Stewardship Programs

6.1.5 Off-Label Use of Antibiotics

6.2 US

6.3 5EU

6.4 Japan

7 Competitive Assessment

7.1 Overview

7.2 Product Profiles – Beta-Lactam Antibiotics

7.2.1 Overview

7.2.2 Fixed Dose Beta-Lactam Combination Drugs

7.2.3 Monobactam antibiotics

7.2.4 Carbapenems

7.2.5 Cephalosporins

7.3 Product Profiles – Fluoroquinolones

7.3.1 Overview

7.3.2 Levofloxacin (numerous brand names)

7.3.3 Ciprofloxacin (numerous brand names)

7.3.4 Moxifloxacin (numerous brand names)

7.4 Product Profiles – Polymixins

7.4.1 Overview

7.4.2 Forecast

7.5 Product Profiles – Aminoglycosides

7.5.1 Overview

7.5.2 Amikacin (numerous brand names)

7.5.3 Gentamicin (numerous brand names)

7.5.4 Tobramycin (numerous brand names)

7.6 Product Profiles – Tetracyclines

7.6.1 Tygacil (tigecycline)

7.7 Product Profiles – Other Antibiotics

8 Unmet Needs Assessment and Opportunity Analysis

8.1 Overview

8.2 Novel Approaches in Drug Development to Address Antibiotic Resistance

8.2.1 Unmet Need

8.2.2 Gap Analysis

8.2.3 Opportunity

8.3 Novel Broad-Spectrum Antibiotics

8.3.1 Unmet Need

8.3.2 Gap Analysis

8.3.3 Opportunity

8.4 Antibiotics Positioned as Pathogen- and Resistance-Specific Therapies

8.4.1 Unmet Need

8.4.2 Gap Analysis

8.4.3 Opportunity

8.5 Expansion of Antimicrobial Stewardship Programs and Awareness

8.5.1 Unmet Need

8.5.2 Gap Analysis

8.5.3 Opportunity

8.6 Financial Incentives for Drug Development and Collaborative Efforts Between Governments/Non-Profits/For-Profits

8.6.1 Unmet Need

8.6.2 Gap Analysis

8.6.3 Opportunity

8.7 Improved Diagnostics for Pathogens and Resistance Patterns

8.7.1 Unmet Need

8.7.2 Gap Analysis

8.7.3 Opportunity

8.8 Improving the Safety and Administration Profile of Antibiotics

8.8.1 Unmet Need

8.8.2 Gap Analysis

8.8.3 Opportunity

8.9 Improved Clinical Trial Design

8.9.1 Unmet Need

8.9.2 Gap Analysis

8.9.3 Opportunity

8.10 Improved Prevention of Healthcare-Associated Infections

8.10.1 Unmet Need

8.10.2 Gap Analysis

8.10.3 Opportunity

9 Pipeline Assessment

9.1 Overview

9.2 Promising Drugs in Clinical Development

9.2.1 Antibiotics

9.2.2 Antibodies

9.3 Other Drugs in Development

10 Current and Future Players

10.1 Overview

10.2 Trends in Corporate Strategy

10.3 Company Profiles – Current Players

10.3.1 Pfizer

10.3.2 Merck& Co.

10.3.3 The Medicines Company

10.3.4 Shionogi & Co., Ltd.

10.3.5 Tetraphase Pharmaceuticals Inc.

10.3.6 MerLion Pharmaceuticals Pte., Ltd.

10.3.7 Achaogen

10.3.8 Aridis Pharmaceuticals

10.3.9 MedImmune LLC

10.3.10 Allergan

10.4 Other Companies With Early-Stage Products

10.4.1 Roche/Genentech

10.4.2 Wockhardt Ltd.

10.4.3 Allecra

10.4.4 Zavante

11 Market Outlook

11.1 Global Markets

11.1.1 Forecast

11.1.2 Drivers and Barriers – Global Issues

11.2 US

11.2.1 Forecast

11.2.2 Key Events

11.2.3 Drivers and Barriers

11.3 5EU

11.3.1 Forecast

11.3.2 Key Events

11.3.3 Drivers and Barriers

11.4 Japan

11.4.1 Forecast

11.4.2 Key Events

11.4.3 Drivers and Barriers

12 Appendix

12.1 Bibliography

12.2 Abbreviations

12.3 Methodology

12.3.1 Forecasting Methodology

12.3.2 Suspected Infections and Diagnosed Patients

12.3.3 Percent Drug-Treated Patients

12.3.4 Antibiotic Resistance Patterns

12.3.5 Drugs Included in Each Therapeutic Class

12.3.6 Launch and Patent Expiry Dates

12.3.7 General Pricing Assumptions

12.3.8 Individual Drug Assumptions

12.3.9 Generic Erosion

12.3.10 Pricing of Pipeline Agents

12.4 Primary Research – Key Opinion Leaders Interviewed for This Report

12.5 Primary Research – Prescriber Survey

12.6 About the Authors

12.6.1 Analyst

12.6.2 Therapy Area Director

12.6.3 Epidemiologist

12.6.4 Reviewers

12.6.5 Global Director of Therapy Analysis and Epidemiology

12.6.6 Global Head and EVP of Healthcare Operations and Strategy

12.7 About GlobalData

12.8 Contact Us

12.9 Disclaimer

Frequently asked questions

PharmaPoint: Healthcare-Associated Gram-Negative Infections – Global Drug Forecast and Market Analysis to 2026 thematic reports
Currency USD

Can be used by individual purchaser only


Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

PharmaPoint: Healthcare-Associated Gram-Negative Infections – Global Drug Forecast and Market Analysis to 2026 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Innovation in pharma: transdermal drug delivery
$250 | November 2023
Synthetic Biology - Thematic Intelligence
$995 | November 2023
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at PharmaPoint: Healthcare-Associated Gram-Negative Infections – Global Drug Forecast and Market Analysis to 2026 in real time.

  • Access a live PharmaPoint: Healthcare-Associated Gram-Negative Infections – Global Drug Forecast and Market Analysis to 2026 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.